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Abstract
Aims/hypothesis We investigated whether biochemical car-
diovascular risk factors and/or markers of subclinical cardio-
vascular disease were associated with the development of re-
duced renal function in people with type 2 diabetes.
Methods A cohort of 1066 Scottish men and women aged
60–74 years with type 2 diabetes from the Edinburgh Type 2
Diabetes Study were followed up for a median of 6.7 years.
New-onset reduced renal function was defined as two eGFRs
<60 ml−1 min−1 (1.73 m)−2 at least 3 months apart with
a > 25% decline from baseline eGFR. Ankle brachial pressure
index (ABI), N-terminal pro-B-type natriuretic peptide (NT-
proBNP) and high-sensitivity troponin T (hsTnT) were
measured at baseline. Pulse wave velocity (PWV) and carotid
intima media thickness were measured 1 year into follow-up.
Data were analysed using Cox proportional hazards models.
Results A total of 119 participants developed reduced renal
function during follow-up. ABI, PWV, NT-proBNP and
hsTnTwere all associated with onset of decline in renal func-
tion following adjustment for age and sex. These associations
were attenuated after adjustment for additional diabetes
renal disease risk factors (systolic BP, baseline eGFR,
albumin:creatinine ratio and smoking pack-years), with the
exception of hsTnTwhich remained independently associated
(HR 1.51 [95% CI 1.22, 1.87]). Inclusion of hsTnT in a pre-
dictive model improved the continuous net reclassification
index by 0.165 (0.008, 0.286).
Conclusions/interpretation Our findings demonstrate an as-
sociation between hsTnT, a marker of subclinical cardiac is-
chaemia, and subsequent renal function decline. Further re-
search is required to establish the predictive value of hsTnT
and response to intervention.
Keywords Cardiovascular disease . Chronic kidney disease .
Diabetic nephropathy . Troponin . Type 2 diabetesmellitus
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Introduction
The development of reduced renal function and chronic kid-
ney disease (CKD) in people with type 2 diabetes predicts an
increase in both morbidity and mortality rates [1]. As a result,
improved methods for identifying high-risk individuals need
to be established to enable early, targeted interventions to pre-
vent decline of renal function and improve treatment out-
comes. Early research investigating the development of
CKD in people with type 2 diabetes indicated that the predom-
inant aetiology was diabetic nephropathy [2], the hallmark of
which is the development of albuminuria. Albumin:creatinine
ratio (ACR) is, therefore, commonly used clinically to identify
individuals with type 2 diabetes who have developed CKD
and are at high risk of progression [2, 3]. However, more
recently, a growing number of studies have demonstrated that
many people with type 2 diabetes develop a progressive dete-
rioration of renal function in the absence of albuminuria [4, 5].
It has been proposed that many people with type 2 diabetes
develop impaired renal function as a result of vascular disease,
rather than classical diabetic nephropathy, consistent with ACR
being a poor kidney disease biomarker inmany individuals [5]. If
correct, then it would be reasonable to hypothesise that cardio-
vascular disease (CVD) biomarkers may improve on risk stratifi-
cation using conventional risk factors for diabetic CKD. Support
for this hypothesis comes fromprevious studies demonstrating an
association between the development of end-stage renal disease
and biochemical markers of CVD, N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) and high-sensitivity troponin T
(hsTnT), in people with type 2 diabetes, even after adjustment
for eGFR and albuminuria [6, 7]. Markers of subclinical athero-
sclerosis have also been linked with renal disease progression
including ankle brachial pressure index (ABI) and carotid intima
media thickness (cIMT), along with markers of arterial stiffness,
such as pulse wave velocity (PWV). However, some of the
evidence is conflicting and there have been no large longitudinal
studies focusing on people with type 2 diabetes [8–12].
Our study set out to investigate the association between
CVD biomarkers (blood-based and non-blood-based) and
the onset of impaired renal function in a prospective cohort
of people with type 2 diabetes (the Edinburgh Type 2 Diabetes
Study [ET2DS]). We hypothesised that increased levels of
individual CVD risk factors and/or markers of clinical or sub-
clinical CVD would be associated with the development of
clinically significant decline in renal function and, further, that
some of these markers would add predictive value beyond
recognised risk factors for renal disease.
Methods
We performed a prospective cohort study using participants of
the ET2DS. Recruitment and baseline examination for the
ET2DS has been described previously [13, 14]. Briefly, the
ET2DS recruited 1066 men and women aged 60–74 years with
established type 2 diabetes living in the Lothian region of
Scotland between 2006 and 2007. Participants were randomly
selected by sex and 5 year age bands from the Lothian diabetes
register which is a comprehensive database of people with type
2 diabetes living in Lothian. The database includes individuals
attending both hospital diabetes clinics and thosemanaged sole-
ly in primary care. Of the 5454 individuals who were invited to
participate, 1066 were recruited to the study and attended the
baseline research clinic. The ET2DS population has been
shown previously to be largely representative, in terms of age,
HbA1c, duration of diabetes and insulin treatment, of all those
randomly selected to participate [15]. Approval for ET2DS has
been given by the LothianMedical Research Ethics Committee
and all participants have given written consent, including for
follow-up examinations and review of medical records.
At the baseline ET2DS clinic attendance, demographic,
medical history and clinical variables were measured including
BP and ABI. Following an overnight fast, venous blood and
urine samples were obtained for biochemical analysis. The pres-
ence of CVDwas determined using a combination of self-report,
record linkage and ECG data. Presence of CVD was indicated
by a baseline history of transient ischaemic attack (TIA), stroke,
myocardial infarction (MI), angina and/or intermittent claudica-
tion, defined according to previously reported criteria [15].
All blood samples were separated and frozen at −80°C with-
in 1 h of venepuncture, except for samples for creatinine,
HbA1c and glucose analyses for which fresh samples were used.
ACR was measured on a fresh urine sample. All samples were
analysed according to standard protocols in the Department of
Biochemistry, Western General Hospital, Edinburgh, UK.
Plasma C reactive protein (CRP), NT-proBNP and hsTnT
concentrations were measured at the University of Glasgow
laboratories. CRP was assayed using a high-sensitivity
immunonephelometric assay with a BN ProSpec nephelo-
meter (Dade Behring, Milton Keynes, UK) [16]. NT-proBNP
and hsTnT were measured using the Elecsys 2010 electro-
chemiluminescence methods (Roche Diagnostics, Burgess
Hill, UK) calibrated using the manufacturer’s reagents. Plasma
samples for NT-proBNP and hsTnT had been stored at −80°C
for up to 4 years prior to analysis. Manufacturer’s controls were
used with limits of acceptability defined by the manufacturer.
The between batch CVs for NT-proBNPwere 6.7% at a concen-
tration of 131 ng/l and 4.9% at 4602 ng/l. For hsTnT the between
batch CVs were 3.7% at 25.2 ng/l and 2.2% at 2254 ng/l.
For measurement of ABI, brachial, posterior tibial and
dorsalis pedis systolic BP (SBP) were measured in both arms
and both feet using either an aneroid, 6-in. dial, desk standing
sphygmomanometer or a mercury sphygmomanometer
(WBIC, Wenzhou, China). ABI was calculated using the low-
est ankle pressure as the numerator and the highest brachial
pressure as the denominator. ABI results of >1.3 (n = 26) were
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excluded, as very high values may indicate arterial stiffness in
diabetic populations [17].
Participants were assessed for the presence of diabetic ret-
inopathy (DR) using retinal photography. Pupillary dilatation
was carried out followed by standard seven-field non-stereo-
scopic colour photographs being taken of both eyes at 35°
using a high-resolution digital retinal camera. Two trained
optometrists graded all the photographs, working indepen-
dently and according to the scale described by the Early
Treatment Diabetic Retinopathy Study research group [18].
Inter- and intraobserver variations and the validity of this grad-
ing system have previously been evaluated [19]. For each eye,
the maximum grade in any of the seven photographic fields
was determined for each of the characteristic lesions of DR
and was used in defining the final retinopathy levels. The
retinopathy level for a participant was assigned based on the
severity scores of the worst eye. Any discrepancies between
the scores assigned by the two graders were resolved through
discussion between the graders with any unresolved discrep-
ancies being reviewed and arbitrated by an ophthalmologist.
One year after recruitment, all participants who were still
living were invited to attend a further research clinic for as-
sessment of PWV and cIMT. A total of 939 participants
attended. Of the 133 participants not attending, 15 had died
and the remainder were uncontactable, or unable or unwilling
to attend. The baseline characteristics of participants attending
the year 1 clinic were similar to those of the total ET2DS
population suggesting that this group remained largely repre-
sentative of the target general population with type 2 diabetes
[13].
PWV measurements were carried out after participants had
been supine for at least 25 min by obtaining the arterial pulse
wave form at the common carotid and femoral arteries using
the Sphygmo Cor system version 8.0 (At Cor Medical Pty,
Sydney, NSW, Australia). The time delay between the arrival
of the pulse wave at the two points was measured. A tape
measure was used to determine the distance between the ca-
rotid and sternal notch and the distance between sternal notch
and the femoral site. ‘Direct path length’ was calculated by
subtracting the carotid–sternal notch distance from sternal
notch–femoral distance. Where possible, all measurements
were made in duplicate and mean values calculated [20].
cIMT, defined as the distance between the lumen–intima
interface and the media–adventitia interface, was measured
bilaterally in three separate images of the common carotid
artery using a Sonoline Elegra Ultrasound Imaging System
(Siemens Medical Systems, Issaquah, WA, USA).
Mean cIMT was calculated for the right and left com-
mon carotid arteries and the higher of these two values
was used for analyses [21].
Follow-up The Lothian laboratory and Lothian diabetes reg-
ister databases were interrogated and all outpatient or primary
care serum creatinine results from 2005 to May 2014 were
identified. eGFR was calculated from serum isotope dilution
MS–traceable creatinine results using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
[22].
New-onset of reduced renal function was defined as two
eGFRs <60 ml−1 min−1 (1.73 m)−2 at least 3 months apart with
a > 25% decline in eGFR from baseline as per the Kidney
Disease Improving Global Outcomes (KDIGO) clinical prac-
tice guideline for the evaluation and management of CKD
[23].
Data analysis Results are expressed as means (± SD) unless
otherwise stated. Any data that did not conform to the normal
distribution were log10-transformed (e.g. NT-proBNP, hsTnT,
ACR, smoking pack-years) prior to further analysis.
Comparison of variables between groups was performed
using ANOVA or χ2 test for continuous and categorical
values, respectively. The association between baseline vari-
ables and new-onset renal function decline was assessed by
Cox proportional hazards. HRs for continuous variables relate
to a 1 SD increase. Model fit was assessed using C statistics,
continuous net reclassification index (NRI) and integrated dis-
crimination index (IDI). Continuous NRI and IDI were calcu-
lated as it has been suggested that changes in C statistic are not
sensitive enough to accurately reflect the added value that new
biomarkers bring to a model [24]. Continuous NRI provides
an indication of how many individuals are ‘reclassified’ in the
correct direction by the new model compared with the refer-
ence model; whilst IDI quantifies the difference in discrimi-
nation slopes between the reference model and new model.
All analyses were performed using the SPSS statistics soft-
ware package (version 21.0; IBM, Armonk, NY, USA) apart
from C statistic, continuous NRI and IDI calculations which
were performed using R (version 3.1.1, R Foundation for
Statistical Computing, Vienna, Austria). A p value of <0.05
was considered to be significant.
Results
Baseline and follow-up renal function data were available for
1048 of the 1066 ET2DS participants. Participants with evi-
dence of CKD at baseline (n = 347, 33%), defined as either an
eGFR <60 ml−1 min−1 (1.73 m)−2 on two or more consecutive
eGFRs at least 3 months apart and/or albuminuria (ACR
>2.5 mg/mmol in men; >3.5 mg/mmol in women) on two
out of three consecutive urine samples, were excluded from
further analysis. The median participant follow-up was
6.7 years with an interquartile range of 6.4–7.1 years.
Of the 701 participants who did not have evidence of CKD
at baseline, 119 (17%) developed reduced renal function dur-
ing follow-up. Serial ACR results for these 119 participants
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were specifically reviewed and, of these, 101 (85%) did not
have preceding albuminuria.
A comparison of baseline variables in participants accord-
ing to whether or not they developed reduced renal function is
shown in Table 1. As expected, participants who were older,
had a lower baseline eGFR, longer diabetes duration and
higher HbA1c were more likely to develop renal impairment.
There was no association with baseline ACR. Of the cardio-
vascular biomarkers analysed, the presence of CVD, lower
ABI, higher PWV, NT-proBNP and hsTnTwere all associated
with the onset of reduced renal function.
The Cox regression analysis of the relationship between
baseline variables and the onset of reduced renal function is
shown in Table 2. There was a log-linear association between
all the CVD biomarkers and reduced renal function with no
evidence of non-linearity. Of the cardiovascular biomarkers,
higher NT-proBNP, hsTnT and PWV, and lower ABI were all
associated with renal function decline after adjustment for age
and sex (Model 1). Further adjustment for all the classical
diabetic kidney disease risk factors (HbA1c, SBP, diabetes
duration, ACR, eGFR, smoking pack-years) was carried out
(Model 2). Following this adjustment, higher hsTnT (HR 1.51
[95% CI 1.22, 1.87]; p < 0.001) continued to be strongly
associated with the onset of renal impairment. The relation-
ship between the other CVD biomarkers and renal function
decline was attenuated to borderline. The main loss of signif-
icance for NT-proBNP occurred following the introduction of
baseline eGFR into the model; whilst it was the introduction
of smoking pack-years into the model that attenuated the re-
lationship between PWVand ABI with decline in renal func-
tion (data not shown). There was no evidence of any interac-
tion effects for any of the main adjustment variables (data not
shown).
We did not find evidence of an association between the
baseline presence of DR, lipid levels, diastolic BP (DBP),
CRP and cIMTwith decline in renal function.
Figure 1 displays the onset of renal function decline over
time stratified according to baseline hsTnT quartiles. Sex spe-
cific quartiles were used to correct for the lower hsTnT levels
found in women [25]. The relationship between hsTnT quar-
tile and the onset of decline in renal function was consistent
across both sexes and therefore a single Kaplan–Meier plot
with the quartiles combined for both sexes is shown. The HR
for participants in the highest baseline quarter was 1.60 (95%
CI 1.03, 2.50; p = 0.038) for women and 2.93 (1.43, 6.03;
p = 0.003) for men.
The incremental benefit of adding hsTnT to a baseline
model of established kidney disease risk factors (age, sex,
SBP, HbA1c, diabetes duration, baseline ACR, eGFR and
smoking pack-years) was assessed. Following the addition
of hsTnT to the model there was a non-significant improve-
ment in C statistic from 0.772 (95% CI 0.717, 0.829) to 0.783
(0.728, 0.837). There was a significant improvement in
continuous NRI of 0.165 (0.008, 0.286; p = 0.04) and IDI of
0.029 (0.002, 0.071; p = 0.007).
Discussion
To our knowledge this is the first study to examine such a
comprehensive range of CVD biomarkers (both physical and
blood-based cardiovascular phenotyping) and their relation-
ship with the onset of renal function decline in a large longi-
tudinal study of people with type 2 diabetes.
Our study confirms the tremendous burden of kidney dis-
ease for people with type 2 diabetes with 347 (33%) of the
1066 participants in the ET2DS cohort having CKD at base-
line and a further 119 (17%) developing a clinically relevant
decline in renal function during follow-up.
It has traditionally been believed that significant albumin-
uria occurs prior to the development of functional renal im-
pairment in CKD in people with type 2 diabetes. Therefore,
ACR is used to screen for the development of CKD and iden-
tify individuals at high risk of progression [26, 27]. However,
of the 119 participants who developed reduced renal function
during follow-up, the largest proportion (n = 101, 85%) did
not develop albuminuria prior to a decline in renal function
during the follow-up period. The proportion is higher than that
found in the United Kingdom Prospective Diabetes Study
(UKPDS) where 51% of those developing renal impairment
did not have preceding albuminuria [28]. This may be due to
the fact that participants with albuminuria at baseline were
excluded, the participants in our cohort were older or that
more people are now diagnosed with diabetes earlier so that
progression of renal disease has been slowed [29].
Furthermore, almost two-thirds of participants were pre-
scribed renin-angiotensin system inhibitors at baseline and
this may have masked the presence of albuminuria. Finally,
we do not have information regarding changes in medication
during the study, it is possible that for some participants a
decline in eGFR may reflect the introduction of renin-
angiotensin system inhibitor or diuretic rather than progres-
sion of intrinsic renal disease.
The presence of microvascular diabetes complications,
such as DR, has also traditionally been considered to be a risk
factor for the development of CKD in people with type 2
diabetes [30]. However, our study did not find any evidence
of an association between the baseline presence of DR and
decline in renal function. Overall, the large number of partic-
ipants developing renal impairment in the absence of either
albuminuria or retinopathy indicates that the traditional clini-
cal paradigm of diabetic nephropathy needs to be re-evaluated
as it does not appear to reflect the pathological process occur-
ring in the majority of people with type 2 diabetes and declin-
ing renal function [5].
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Table 1 Comparison of baseline variables in participants according to onset of renal function decline
Renal function decline
N Yes (n = 119) No (n = 582) p
Established kidney disease risk factors
Sex (men), n (%) 701 51 (43%) 302 (52%) 0.059
Age, years 701 68.8 ± 3.7 67.0 ± 4.1 <0.001
SBP, mmHg 701 135 ± 17 132 ± 15 0.064
eGFR, ml−1 min−1 (1.73 m)−2 701 80.2 ± 9.5 87.2 ± 10.4 <0.001
Diabetes durationa, years 694 6.9 ± 1.0 5.3 ± 1.0 0.002
ACR, n (%) 701
≤ 0.5 mg/mmol 81 (68%) 422 (73%)
0.6–1.5 mg/mmol 24 (20%) 106 (18%) 0.159
1.6–2.5 mg/mmol 11 (9%) 38 (7%)
2.6–3.5 mg/mmol 4 (3%) 15 (3%)
HbA1c (DCCT%) 701 7.6 ± 1.2 7.3 ± 1.1 0.003
HbA1c (IFCC mmol/mol) 60 ± 9.5 56 ± 9.3
Smoking, n (%) 701
Never 47 (39%) 239 (41%)
Former 55 (46%) 264 (45%) 0.607
Current 18 (15%) 78 (13%)
Medications, n (%) 699
ACE/ARB 83 (70%) 347 (60%) 0.043
Antiplatelets 699 73 (61%) 372 (64%) 0.564
Statins 699 99 (83%) 468 (81%) 0.525
Prevalent microvascular disease 685
Retinopathy, n (%)
None 78 (66%) 412 (73%)
Mild 37 (31%) 142 (25%) 0.256
Moderate/severe 4 (3%) 12 (2%)
Prevalent CVD
CVD, n (%) 701 47 (40%) 163 (28%) 0.016
CVD risk factors
BMI, kg/m2 701 30.9 ± 5.5 31.3 ± 5.3 0.400
DBP, mmHg 701 69 ± 9 70 ± 9 0.384
Total cholesterol, mmol/l 690 4.3 ± 1.0 4.3 ± 0.9 0.727
HDL-cholesterol, mmol/l 690 1.3 ± 0.3 1.3 ± 0.4 0.739
Cholesterol:HDL-cholesterol ratio 689 3.4 ± 1.0 3.5 ± 1.1 0.686
CRPa, mg/l 683 2.2 ± 3.4 1.7 ± 3.2 0.069
Subclinical markers of CVD
cIMT (year 1), mm 613 1.00 ± 0.10 0.98 ± 0.17 0.572
PWV (year 1), mm/s 583 9.8 ± 2.3 9.2 ± 2.1 0.013
ABI 681 0.96 ± 0.18 1.00 ± 0.15 0.013
Biochemical markers of CVD
NT-proBNPa, ng/l 688 82.9 ± 2.8 58.7 ± 2.9 0.001
hsTnTa, ng/l 695 9.8 ± 1.7 8.4 ± 1.6 0.001
Data presented are mean ± SD for continuous variables
a Geometric mean ± SD
ANOVA for continuous variables; χ2 for categorical variables
ARB, angiotensin-receptor blocker
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Association between renal function decline and cardiovas-
cular biomarkers/risk factors Higher levels of hsTnT, NT-
proBNP and PWV, and lower ABI levels were all associated
with renal function decline following adjustment for age and
sex. After further adjustment for classical kidney disease risk
factors, including eGFR and smoking pack-years, the strong
association between baseline hsTnT level and renal function
decline persisted, with men in the highest hsTnT quartile
demonstrating an almost threefold increase in risk.
Importantly, the addition of hsTnT to a risk prediction model
also provided incremental value over standard CKD risk
factors in predicting renal function decline with a substantial
continuous NRI improvement of 16.3% (p = 0.02). These
results indicate that hsTnT may be useful for identifying
individuals at increased risk of developing a clinically sig-
nificant decline in renal function. In addition, hsTnT may
have utility in clinical trials through improving the identifi-
cation of participants at high risk of developing renal disease
and, as a result, enabling more effective evaluation of
interventions.
There are few prior data on the prognostic value of cardio-
vascular biomarkers in people with type 2 diabetes for the
prediction of decline in renal function. Support for our find-
ings comes from studies demonstrating an association
Table 2 Cox regression analysis showing the relationship between cardiovascular and other risk factors and the development of renal function decline
Model 1 Model 2
HR 95% CI p HR 95% CI p
Established kidney disease risk factors
Age 1.58 1.32, 1.90 <0.001 1.39 1.14, 1.70 0.001
Sex (women) 1.55 1.08, 2.23 0.018 2.01 1.35, 2.99 0.001
SBP 1.15 0.96, 1.37 0.129 1.24 1.03, 1.49 0.021
HbA1c 1.26 1.10, 1.45 0.001 1.30 1.09, 1.54 0.003
log10 Diabetes duration 1.38 1.15, 1.66 0.001 1.32 1.07, 1.62 0.009
eGFR 0.50 0.42, 0.60 <0.001 0.47 0.39, 0.57 <0.001
log10 ACR +1 1.14 0.96, 1.34 0.127 1.07 0.87, 1.25 0.662
log10 Smoking pack-years +1 1.23 1.01, 1.49 0.038 1.33 1.09, 1.64 0.006
Prevalent microvascular disease
Retinopathy
No retinopathy
Mild 1.32 0.89, 1.95 0.168 0.96 0.64, 1.44 0.836
Moderate/severe 1.60 0.58, 4.40 0.359 0.78 0.26, 2.25 0.630
Prevalent CVD
CVD (history of MI, angina, claudication, TIA/stroke) 1.56 1.09, 2.30 0.017 1.20 0.79, 1.80 0.394
CVD risk factors
DBP 1.02 0.84, 1.23 0.883 0.96 0.77, 1.20 0.722
Total cholesterol 0.95 0.79, 1.15 0.615 0.90 0.74, 1.09 0.261
HDL-cholesterol 0.90 0.74, 1.09 0.294 0.89 0.73, 1.09 0.263
Cholesterol:HDL-cholesterol ratio 1.02 0.85, 1.22 0.863 0.99 0.81, 1.22 0.936
log10 hsCRP 1.19 0.99, 1.43 0.070 1.35 0.92, 1.99 0.130
Subclinical markers of CVD
cIMT 1.06 0.87, 1.29 0.581 1.07 0.88, 1.30 0.492
PWV 1.25 1.03, 1.53 0.026 1.09 0.99, 1.19 0.077
ABI 0.83 0.70, 0.97 0.022 0.48 0.14, 1.66 0.247
Biochemical markers of CVD
log10 NT-proBNP 1.35 1.12, 1.62 0.002 1.18 0.96, 1.45 0.108
log10 hsTnT 1.56 1.30, 1.87 <0.001 1.51 1.22, 1.87 <0.001
Data are HR (95% CI) by Cox regression analysis
HR for continuous variables relate to a 1 SD increase
Model 1, adjusted for age and sex; Model 2, adjusted for established CKD risk factors (age, sex, SBP, HbA1c, log10 ACR+1, baseline eGFR, duration of
diabetes, log10 smoking pack-years +1)
Diabetologia
between troponin levels and diabetic nephropathy [7] and pro-
gression to end-stage renal disease [6].
In addition to providing quantitative data on risk predic-
tion, our findings that subclinical changes in hsTnT precede
the development of renal impairment in people with type 2
diabetes also raise questions about the pathophysiological
mechanisms underlying the development of CKD.
The physiological basis for an association between hsTnT
and incident CKD is not well established. hsTnT is to some
extent cleared by the kidneys and hsTnT levels must therefore
be interpreted in relation to renal function [31, 32]. However,
the relationship between hsTnT and renal outcomes remained
strong (p < 0.001) even after adjusting for baseline eGFR.
hsTnT is a marker of myocardial injury and micronecrosis, it
is therefore possible that cardiac vascular disease, reflected by
slightly raised hsTnT levels, could be paralleled by vascular
disease in other organs, including the kidneys [33].
Baseline levels of PWVand ABI were associated with the
onset of renal impairment but these associations were attenu-
ated to the null on multivariate analysis, with the main loss of
significance occurring following adjustment for smoking
pack-years. Therewas no evidence of any association between
cIMT and renal impairment. Our findings are in contrast to
prospective studies on the general population which have
found ABI, PWV and cIMT to be independently associated
with renal function decline and/or the onset of CKD [34–36].
The differing results could be due to the careful adjustment for
smoking history based on calculated pack-years in our study
or the different course/drivers of renal disease in the general
population relative to people with diabetes. Furthermore,
cIMT and PWV were measured 1 year into follow-up in our
study, which may have limited their predictive potential.
Finally, our cohort is modest in size and event numbers, and
therefore not sufficiently powered to detect a small association
between these cardiovascular biomarkers and renal disease.
Strengths and limitations This study has several strengths
including the prospective nature, length of follow-up and large
cohort. Furthermore, the review of laboratory records to ob-
tain serial serum creatinine results ensured that the follow-up
data were almost entirely complete and that a rigorous, inter-
nationally recognised, definition of decline in renal function
based on more than one eGFR result could be applied [23].
Additionally, the majority of the participants had undergone
detailed cardiovascular phenotyping, allowing us to investi-
gate both structural and biochemical cardiovascular bio-
markers simultaneously for the first time.
We acknowledge that our study has limitations. First, we
used serum creatinine to calculate eGFR rather than obtaining
a directly measured GFR. eGFRs may be less accurate in
people with higher levels of renal function; therefore, we
employed the CKD-EPI equation, which has been shown to
be more accurate at estimating GFR at higher levels of renal
function than the widely used Modification of Diet in Renal
Disease equation [22]. Furthermore, to avoid inclusion of par-
ticipants who crossed the eGFR <60 ml−1 min−1 (1.73 m)−2
threshold despite only a small absolute reduction in renal
function, we only included those who also had >25% reduc-
tion from baseline renal function as recommended by KDIGO
[23]. Second, the PWV and cIMT measurements were per-
formed 1 year into follow-up and it is therefore possible that
this may have impacted on the ability of our study to assess the
association between these variables and renal disease.
However, exclusion of the 18 participants who developed an
endpoint less than 1 year into follow-up did not significantly
alter the results of the analysis for either cIMT or PWV (data
not shown). Third, because of limited baseline plasma avail-
ability it was not possible to carry out NT-proBNP and hsTnT
measurements on all participants. Fourth, plasma samples
were stored frozen prior to NT-proBNP and troponin analysis.
It has previously been reported that both NT-proBNP and
troponin T levels may fall slightly during long-term
(>12 months) storage; therefore, it is possible that some sam-
ple degradation may have occurred. However, studies have
shown that levels after long-term storage remain highly corre-
lated with baseline levels and that the amount of degradation is
likely to be small (<6%) [37, 38]. Finally, due to the observa-
tional design of this study, it was not possible to evaluate the
potential for causality in any of the reported associations.
In conclusion, this study demonstrates the significant bur-
den of CKD for people with type 2 diabetes and the need for
new, more efficacious biomarkers to enable improved identi-
fication of individuals at high risk of kidney disease
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Fig. 1 Kaplan–Meier curve demonstrating onset of renal function de-
cline stratified according to baseline hsTnT quartile (for men Q1 3.28–
8.19, Q2 8.20–10.24, Q3 10.25–13.60, Q4 13.61–284.30 ng/l; for women
Q1 2.90–5.31, Q2 5.32–6.87, Q3 6.88–9.13, Q4 9.14–39.94 ng/l). Thick
black line, Q1; thin black line, Q2; dashed line, Q3; dotted line, Q4
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development and progression. The findings in this study of an
association between subclinical CVD biomarkers/risk factors,
such as hsTnT, and subsequent decline in renal function is
therefore important. Further research is required to establish
the predictive value and thus clinical utility of these bio-
markers (and notably automated hsTnT measurements are
widely available in most laboratories) and their response to
interventions known to lessen risk of CKD in people with
diabetes.
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